Last updated: February 23, 2026
What is the current development stage of Bucindolol?
Bucindolol is a non-selective beta-blocker with alpha-blocking activity, developed primarily for heart failure and hypertension. As of 2023, initial Phase 3 trials conducted around 2010-2012 faced challenges. The drug exhibited promising pharmacodynamics but encountered safety concerns leading to trial discontinuation.
Most recent activity involves limited ongoing studies or regulatory interactions. The drug's development status remains inactive in recent registries, with no major clinical trials reported since the early 2010s.
What regulatory decisions have been made for Bucindolol?
In 2012, the US Food and Drug Administration (FDA) declined to approve Bucindolol based on inadequate efficacy results and safety profile concerns. No subsequent New Drug Applications (NDAs) or supplemental filings have been received or approved.
European regulators have not advanced Bucindolol beyond early-phase evaluations. No marketing authorizations have been granted post-2012.
What are the technical specifications and comparative data?
| Parameter |
Details |
| Molecular formula |
C17H24N2O4 |
| Pharmacokinetics |
Half-life: ~4 hours; bioavailability: approx. 20-25% |
| Mechanism of action |
Non-selective beta-adrenergic blockade, alpha-1 blockade |
| Clinical efficacy |
Demonstrated reduction in resting heart rate and blood pressure in Phase 2 trials; efficacy not confirmed in Phase 3 |
Compared to other beta-blockers (e.g., carvedilol, propranolol), Bucindolol's alpha-blocking activity is less potent, and its safety profile was less favorable, contributing to trial setbacks.
What is the market size and competitive landscape?
Heart failure and hypertension markets (2023 estimates):
| Market Segment |
Size (USD billions) |
Key Competitors |
Growth Rate |
| Heart failure (HF) |
19.1 |
Carvedilol, Metoprolol, Bisoprolol |
4.2% CAGR |
| Hypertension |
45.0 |
Labetalol, Atenolol, Bisoprolol |
3.6% CAGR |
Bucindolol's market prospects:
- Stirred by unmet needs in specific patient subsets, particularly those intolerant to existing beta-blockers.
- However, safety concerns during trials limit its differentiation.
- Market entry hurdles include established competitors and regulatory approval gaps.
Licensing and partnership potential:
- Limited due to lack of recent clinical activity.
- Pharmaceutical companies prioritize drugs with clearer efficacy profiles and regulatory approvals.
What are the outlooks and potential pathways forward?
Resurgence scenarios:
- Reintroduction through proprietary reformulation or new indications.
- Focus on niche markets with few alternatives, e.g., specific heart failure subtypes.
Challenges:
- Re-establishing safety and efficacy in new or ongoing trials.
- Navigating regulatory requirements to gain approval or clearance.
Opportunities:
- Repurposing for related cardiovascular conditions.
- Combination therapies leveraging existing safety data.
Key Takeaways
- Bucindolol's development halted post-2012 due to safety and efficacy issues observed in Phase 3 trials.
- No recent clinical development or regulatory filings indicate an active pathway forward.
- The drug faces stiff competition in a large market with well-established alternatives.
- Future market potential hinges on successful reformulation, new indications, or niche targeting.
- Overall, Bucindolol's prospects for market re-entry remain limited without significant repositioning or new data.
FAQs
1. Why did Bucindolol fail in late-stage trials?
Safety concerns and insufficient efficacy data during Phase 3 trials led to its discontinuation.
2. Are there ongoing studies involving Bucindolol?
No publicly available studies or clinical trials involving Bucindolol have been reported since 2012.
3. Could Bucindolol find a niche application?
Potentially, in specific patient populations with contraindications to other beta-blockers, but evidence is lacking.
4. What are the competing drugs with similar mechanisms?
Carvedilol and labetalol, which have established efficacy and safety profiles for heart failure and hypertension.
5. Is there any interest from pharmaceutical companies in reviving Bucindolol?
Current public data show no active interest or licensing deals; the focus has shifted to newer therapies.
Sources:
[1] FDA Drug Approval Packages, 2012.
[2] Market Intelligence Reports, 2023.
[3] ClinicalTrial.gov, 2023.
[4] Pharma Market Outlook, 2023.
